Cannabidiol and Other Cannabinoids in Demyelinating Diseases
Open Access
- 15 March 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (6), 2992
- https://doi.org/10.3390/ijms22062992
Abstract
A growing body of preclinical evidence indicates that certain cannabinoids, including cannabidiol (CBD) and synthetic derivatives, may play a role in the myelinating processes and are promising small molecules to be developed as drug candidates for management of demyelinating diseases such as multiple sclerosis (MS), stroke and traumatic brain injury (TBI), which are three of the most prevalent demyelinating disorders. Thanks to the properties described for CBD and its interesting profile in humans, both the phytocannabinoid and derivatives could be considered as potential candidates for clinical use. In this review we will summarize current advances in the use of CBD and other cannabinoids as future potential treatments. While new research is accelerating the process for the generation of novel drug candidates and identification of druggable targets, the collaboration of key players such as basic researchers, clinicians and pharmaceutical companies is required to bring novel therapies to the patients.This publication has 112 references indexed in Scilit:
- Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stressCell Death & Disease, 2012
- A Neurovascular Perspective for Long-Term Changes After Brain TraumaTranslational Stroke Research, 2011
- Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis‐like disease in C57BL/6 miceBritish Journal of Pharmacology, 2011
- Hypoxic-Ischemic Encephalopathy in the Term InfantClinics in Perinatology, 2009
- Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and painExpert Opinion on Investigational Drugs, 2007
- Guillain-Barré Syndrome and Preceding Infection with Campylobacter, Influenza and Epstein-Barr Virus in the General Practice Research DatabasePLOS ONE, 2007
- Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitroBritish Journal of Pharmacology, 2007
- Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppressionProceedings of the National Academy of Sciences of the United States of America, 2006
- Demyelinating diseasesJournal of Clinical Pathology, 2006
- Chemical constituents of marijuana: The complex mixture of natural cannabinoidsLife Sciences, 2005